Partner Headlines - AMGN

  1. Gilead Gets Wall Street Love After Q2 Earnings Beat

    IBD
  2. Amgen Stock Clears Buy Point Ahead Of Earnings

    IBD
  3. Is More M&A On The Way For Large-Cap Biotechs?

    Benzinga
  4. Biotech NantKwest Stock Surges On 1st Day Of Trading

    IBD
  5. Benzinga's M&A Chatter for Monday July 27, 2015

    Benzinga
  6. A Big Day For Biotech And It's Not Going So Well

    Benzinga
  7. Regeneron/Sanofi PCSK9 Cholesterol Drug Wins FDA OK

    IBD
  8. US Stock Futures Mixed; All Eyes On Apple, Microsoft Earnings

    Benzinga
  9. Why Big Biotech Could Have Another Leg Up

    Benzinga
  10. Perrigo Company Is Strong But Overvalued

    GuruFocus
  11. Regeneron, Amgen Downgraded As Biotech Seen Slowing

    IBD
  12. Benzinga's Top Downgrades

    Benzinga
  13. Large-Cap Biotechs Poised For Second-Half Rally, RBC Says

    Benzinga
  14. Benzinga's Top #PreMarket Losers

    Benzinga
  15. UBS Downgrades Amgen On 'Waiting Game,' Removes Brodalumab From ...

    Benzinga
  16. US Stock Futures Jump Ahead Of Jobless Claims Data

    Benzinga
  17. What Is Beyond Vision-Loss Blockbuster For Regeneron?

    IBD
  18. Amgen Among 3 Medical Giants With Healthy Payouts

    IBD
  19. Evercore ISI Analyst Breaks Down Amgen's IPR Against AbbVie's ...

    Benzinga
  20. Biotech Short-Sellers Prefer Amgen To Gilead Sciences

    Benzinga
  21. Alder Bio Up As Credit Suisse Lauds Migraine Drug

    IBD
  22. ProShares Releases 2 New Leveraged Biotech ETFs

    Benzinga
  23. An Ebola-Fighting Portfolio For The Present...And The Future

    Benzinga
  24. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  25. Biotech ETFs Hit New 2015 Highs

    Benzinga
  26. Teva Migraine Drug Succeeds In Midstage Trial

    IBD
  27. Activist Hedge Fund Manager Has Strong Focus on Health Care Stocks

    GuruFocus
  28. Why Drugmaker AbbVie Can Power Past Patent Expiration

    IBD
  29. New Migraine Drugs Could Ease Investors' Headaches

    IBD
  30. FDA Cautious On New Drugs

    IBD
  31. Amgen Cholesterol Drug Repatha Wins FDA Panel Vote

    IBD
  32. Regeneron, Amgen Fall On Cholesterol Drug Worries

    IBD
  33. FDA Panel Backs Regeneron

    IBD
  34. Regeneron/Sanofi Cholesterol Drug Wins FDA Panel Vote

    IBD
  35. FDA Looking at New Drugs to Lower "Bad" Cholesterol

    FoxBusiness
  36. FDA weighs cholesterol fighter

    IBD
  37. Are 4 Top-Rated IBD 50 Drug Stocks On Your Radar?

    IBD
  38. FDA: Cholesterol Drug Works

    IBD
  39. Regeneron/Sanofi Cholesterol Drug Under FDA Scrutiny

    IBD
  40. PRIMECAP Sells Portions of Its Top Two Stakes

    GuruFocus
  41. Amgen And AstraZeneca's Deal On Psoriasis Drug Faces Termination

    GuruFocus
  42. 5 Drugs That Could Be Summer Blockbusters

    IBD
  43. CNBC's Stock Pops & Drops From May 26

    Benzinga
  44. Amgen's Cholesterol Fighting Drug Receives EU Approval

    GuruFocus
  45. Amgen Down After Suicides Kill AstraZeneca Deal

    IBD
  46. Morgan Stanley Found This 'Unexpected Negative' At Amgen

    Benzinga
  47. 5 Drugs That Could Be Summer Blockbusters

    IBD
  48. Amgen gets cholesterol edge

    IBD
  49. Health Care Sector Delivers Healthy Q1 Results

    IBD
  50. IPO Stock Watch: Alder Soars On Migraine Drug Results

    IBD
  51. US Stock Futures Edge Higher Ahead Of Economic Data

    Benzinga
  52. The Best And Worst ETFs Of The Week Amid Biotech Rebound

    Benzinga
  53. Regeneron Q1 Earnings Beat As Eylea Research Pays Off

    IBD
  54. Crouching Tigers, Hidden Assets - Smead Capital Management

    GuruFocus
  55. Amgen's Decline Could Be A Good Thing

    Benzinga
  56. Should Amgen's T-Vec Results Be Questioned?

    Benzinga
  57. Amgen drug misses fast track

    IBD
  58. Why Baird Is Upgrading DaVita Healthcare

    Benzinga
  59. Biotechs Weigh On Nasdaq, But Apple, Twitter Hold Firm

    IBD
  60. Amgen Reports An Upbeat Q1 Earnings

    GuruFocus
  61. Stocks Strengthen; Tesla Motors Rises On Battery News

    IBD
  62. Stocks Mildly Higher; China Nods To Visa, MasterCard

    IBD
  63. Amgen, Illumina Crush Views

    IBD
  64. Amgen, Illumina Earnings Hot, Intuitive Surgical Not

    IBD
  65. Amgen Tops Q1 Expectations, Shares Gain

    Benzinga
  66. Strategist: Amgen To Move 3% On Q1 Earnings News

    Benzinga
  67. What The Street...And The Crowd Are Watching At Amgen Before ...

    Benzinga
  68. Amgen Inc.'s First Quarter Earnings Preview - What Could Be In ...

    GuruFocus
  69. 5 Biotech Earnings Under The Microscope This Week

    Benzinga
  70. Amgen's First Drug For Cardiovascular Disease Gets The Green ...

    GuruFocus
  71. Why Amgen Might Start To Turn Around

    Benzinga
  72. Amgen Has A Big Launch Coming Up

    Benzinga
  73. AMGEN

    IBD
  74. AbbVie Upgraded On $7.8 Billion Imbruvica Potential

    IBD
  75. Short Sellers Come Back To Biotech Stocks

    Benzinga
  76. Making Money With Charles Payne: 02/25/15

    FoxBusiness
  77. Evercore ISI Technical Analysis: The 'Single Best Idea'

    Benzinga
  78. A Look At Dan Loeb's Diversified 13F

    Benzinga
  79. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  80. Short Sellers Retreat From Biotech Stocks

    Benzinga
  81. FDA Advisory Committee To Review Amgen's Talimogene Laherparepvec

    Benzinga
  82. Dan Loeb Offers Mea Culpa For 'Mediocre' Returns

    Benzinga
  83. Dan Loeb Fourth Quarter Investor Letter

    GuruFocus
  84. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  85. Generic-Drug Makers Soar, And It's Easy To See Why

    IBD
  86. Pfizer Buying Hospira To Inject Growth Into Generics

    IBD
  87. Nuveen's Bob Doll Runs Several Top Funds

    IBD
  88. Biotech Stocks Down Despite Strong Amgen Quarter

    IBD
  89. Credit Suisse Sees Solid Q4 For Amgen

    Benzinga
  90. Amgen Q4 earnings top views

    IBD
  91. Drug Firms Report Good Q4, But Outlook Cloudy

    IBD
  92. Making Money With Charles Payne: 01/27/15

    FoxBusiness
  93. Amgen Beats Q4 Expectations

    Benzinga
  94. Stocks Weaken Late; Apple Jumps After Hours

    IBD
  95. Earnings Scheduled For January 27, 2015

    Benzinga
  96. 5 Big Biotech Earnings Releases To Watch This Week

    Benzinga
  97. Can CAR-T Therapy Live Up To The Biotech IPO Hype?

    IBD
  98. New Guru Jana Partners' Newest Stock Buys

    GuruFocus
  99. Express Scripts Eyes New Price War: Anti-PCSK9 Drugs

    IBD
  100. Cholesterol Drug Costs Eyed

    IBD
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!